4th Annual
HEART in DIABETES
Where the Heart, Kidney and Diabetes Meet in Clinical Practice

FREE LIVE INTERACTIVE ONLINE

AUGUST 21–24, 2020

All content available ON-DEMAND for 90 DAYS following the meeting

www.HEARTiNDIABETES.com
We invite you to join us for the 4th Annual Heart in Diabetes (HiD) Live Interactive Online Medical Conference to be held from August 21-24, 2020. Following the conference, all content will be available on demand for 90 days. 4th HiD live virtual registration is FREE. Click here to register. Attendees may earn up to 28 FREE CME.

Heart in Diabetes is a medical conference representing an educational initiative, which is a combined effort of cardiologists and endocrinologists. To date, the HiD congress has been a rousing success, with progressive growth of participants and impressive evaluations. Overall, attendees at the 3rd annual conference rated the congress a 3.04 out of 4 in terms of overall quality, educational content, and positive impact on knowledge and professional effectiveness.

The 4th Annual Heart in Diabetes (HiD) will convene expert faculty and practicing clinicians in a one-of-a-kind virtual scientific conference to share knowledge and best practices for managing patients with diabetes, heart disease, and various cardiometabolic conditions. Since 2017, this unique forum has enabled clinicians to improve care for patients with diabetes and obesity who have cardiovascular disease and/or chronic kidney disease, often with heart failure. These disorders share many pathological features and often occur in the same individual. Until recently, however, they were managed by different specialists with varying clinical priorities and goals. The strength of HiD is the promotion and development of cross-discipline approaches to the management of these conditions.

Recent trials have demonstrated cardiovascular benefits from agents that control glycemia, lipids, blood pressure, and inflammation in people with diabetes. However, among practicing professionals, including experts, there is a gap in understanding the implications of these new developments in disease management. The conference examines the newest outcome data and develops suggestions for clinicians and recommendations on the proper implementation of the studies results in practice.

HiD is an all “state-of-the-art” clinical program. The agenda will feature an award presentation “Luminary in Cardiometabolic Medicine” to Dr. Eugene Braunwald, who will provide a keynote lecture. This program provides up-to-date clinical science of the Heart in Diabetes through a multidisciplinary interpretation of outcome data and its implications for practice; this from cardiology, endocrine/diabetes, and nephrology points of view. The virtual conference will include joint sessions with Circulation and JACC (Journal of the American College of Cardiology). In addition, the conference will cover sessions on COVID-19 in Diabetes & CVD, Women & CVD, Contemporary Concepts & Management of DM & ASVCD, The Kidney, Technology & Digital Health, Lipids, Antithrombotics in Diabetes, The Liver, Managing Hyperglycemia, Treatment of Diabetes, Heart Failure and will cover Guidelines and Practice Recommendations. The 4th HiD will also feature several virtual abstract presentations from scientists and researchers around the world as well as several Non-CME Industry Supported presentations.
PROGRAM DESCRIPTION:
This CME conference is a unique medical meeting that brings world-renowned clinical leaders in diabetes and cardiovascular disease and practicing clinicians together to improve the care of patients at a high risk of cardiovascular, metabolic, and kidney diseases. This program is designed to evaluate the clinical science aspects of diabetes, obesity, and CVD, focusing on the heart and kidney in diabetes. The goal is to develop appropriate, comprehensive clinical management plans aligning endocrinologists, cardiologists, nephrologists and all other interested clinicians in their understandings of the impact of diabetes and CVD outcome trials on the clinical management of these very high-risk patients.

PROGRAM OBJECTIVES: Upon completion of this meeting, participants should be able to:

• Discuss the role of incretins in the management of obesity, diabetes, and its complications
• Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1-RAs to reduce cardiovascular mortality in patients with T2D
• Evaluate the evidence supporting the use of SGLT2 inhibitors for HF prevention
• Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome
• Evaluate the extent of macro and microvascular disease in diabetes and obesity
• Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia as well as glucose
• Discuss changes in lipid management guidelines
• Evaluate the impact on the clinical practice of new CV outcome trials in patients with diabetes, including CANVAS, LEADER, SUSTAIN 6, and EMPA-REG
• Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
• Implement the best practices for the management of HFrEF
• Describe the relationship between diabetes, obesity, and congestive heart failure
• Describe the role of PCSK9 in lipid elevations and their potential contributions to vascular disease
• Understand the mechanism of action of PCSK9 inhibitors and CETP inhibitors and their impact on CVD
• Design appropriate insulin-based therapeutic regimens for patients with type 2 diabetes
• Describe obesity management based on a complications-centric model
• Evaluate bariatric procedures and surgery as well as devices, and their effect on weight loss, hormones, and long-term outcomes
• Describe optimal use of glucose monitoring devices

TARGET AUDIENCE
This educational initiative is designed for endocrinologists, cardiologists, diabetologists, nephrologists, internists, family physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the prevention and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

THE HID SCIENTIFIC COMMITTEE GRATEFULLY ACKNOWLEDGES

**CORPORATE SUPPORT**

Sapphire: **ESPERION**

Emeral: **AMARIN • ASTRazeneca • BI/LILLY**

**UNRESTRICTED EDUCATIONAL GRANTS**

Premier Educator: **ASTRAZENECA**

Leader Educator: **AMGEN**

Major Educators: **ABBOTT • PFIZER/MERCK ALLIANCE • NOVO NORDISK**

Educator: **LILLY USA • AMARIN PHARMA INC**
# Program 2020

**Welcome & Introduction**

Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD

## Session 1: COVID-19 in DM & CVD

**Chair:** Derek LeRoith, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am – 10:20am</td>
<td>Obesity, a Major Predictor of Mortality by COVID-19: Associations with DM &amp; CVD and Implications for Therapy</td>
<td>Christos S. Mantzoros, MD, PhD</td>
</tr>
<tr>
<td>10:20am – 10:40am</td>
<td>CVD Incidence &amp; MOA in COVID-19: Vascular, Inflammatory &amp; Thrombosis Implications</td>
<td>Mansoor Husain, MD</td>
</tr>
<tr>
<td>10:40am – 11:00am</td>
<td>Ongoing Research of COVID-19 Complications &amp; Management - Focus on DARE-19</td>
<td>Mikhail N. Kosiborod, MD</td>
</tr>
<tr>
<td>11:00am – 11:20am</td>
<td>Diabetes and the COVID-19 Pandemic</td>
<td>Zachary Bloomgarden, MD</td>
</tr>
<tr>
<td>11:20am – 11:40am</td>
<td>The Impact of COVID-19 on Cardiovascular Care &amp; the Post-Pandemic Future of Cardiovascular Prevention</td>
<td>Laurence Sperling, MD</td>
</tr>
<tr>
<td>11:40am – 12:00pm</td>
<td>Panel Discussion &amp; Live Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

## Session 2: Contemporary Concepts & Management of DM & ASCVD

**Chair:** Laurence Sperling, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00pm – 12:20pm</td>
<td>Epigenetic Modification to Reduce CVD in People with DM</td>
<td>Kausik Ray, MD</td>
</tr>
<tr>
<td>12:20pm – 12:40pm</td>
<td>The Surgical Management of CAD in DM</td>
<td>Michael E. Farkouh, MD</td>
</tr>
<tr>
<td>12:40pm – 1:00pm</td>
<td>Update on CVOTs</td>
<td>Michael H. Davidson, MD</td>
</tr>
<tr>
<td>1:00pm – 1:20pm</td>
<td>Panel Discussion &amp; Live Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

**1:20PM – 2:05PM**

**Product Theater Non-CME Industry Supported Session**

VASCEPA® (icosapent ethyl): Elevating the Standard of Care

Supported by: Amarin

Yehuda Handelsman, MD

## Session 3: Controversies in Lipid Management

**Chair:** Paul S. Jellinger, MD • Kausik Ray, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:05pm – 2:25pm</td>
<td>“Back to the Future” with Lipid Therapy</td>
<td>Norman E. Lepor, MD</td>
</tr>
<tr>
<td>2:25pm – 2:45pm</td>
<td>Should High Triglycerides Be Managed in Addition to a Statin &amp; EPA?</td>
<td>Sergio Fazio, MD, PhD</td>
</tr>
</tbody>
</table>

**Debate: Should Treatment with PCSK9i Be Reserved for LDL > 100**

<table>
<thead>
<tr>
<th>Time</th>
<th>Yes</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:45pm – 3:00pm</td>
<td></td>
<td>Jennifer G. Robinson, MD</td>
</tr>
<tr>
<td>3:00pm – 3:15pm</td>
<td></td>
<td>Steven E. Nissen, MD</td>
</tr>
<tr>
<td>3:15pm – 3:20pm</td>
<td>Rebuttal</td>
<td></td>
</tr>
<tr>
<td>3:20pm – 3:25pm</td>
<td>Rebuttal</td>
<td></td>
</tr>
<tr>
<td>3:25pm – 3:45pm</td>
<td>Panel, Q&amp;A, Audience Voting</td>
<td></td>
</tr>
</tbody>
</table>

## Session 4: Heart in Diabetes with Circulation

**Chairs:** Biykem Bozkurt, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45pm – 3:50pm</td>
<td>Introduction</td>
<td>Biykem Bozkurt, MD, PhD</td>
</tr>
<tr>
<td>3:50pm – 4:05pm</td>
<td>GLP1ra Exenatide and Heart Failure Outcomes</td>
<td>Robert J. Mentz, MD</td>
</tr>
<tr>
<td>4:05pm – 4:20pm</td>
<td>The Diabetes Paradox in Aortic Aneurysm</td>
<td>Joshua Beckman, MD</td>
</tr>
<tr>
<td>4:20pm – 4:35pm</td>
<td>Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of CVD in T1DM</td>
<td>Myra A. Lipes, MD</td>
</tr>
<tr>
<td>4:35pm – 4:50pm</td>
<td>Heart Failure Risk Stratification and Efficacy of SGLT2i in Patients with T2DM</td>
<td>Benjamin M. Scirica, MD</td>
</tr>
<tr>
<td>5:05pm – 5:25pm</td>
<td>Panel, Live Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

**5:25PM – 6:15PM**

**Day 1 Summary, Live Q&A**

Panel: Biykem Bozkurt, MD, PhD • Vivian Fonseca, MD • Yehuda Handelsman, MD • Norman Lepor, MD • Derek Leroith, MD, PhD • Laurence Sperling, MD

## Session 5: Women & CVD

**Chairs:** Norman E. Lepor, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am – 10:20am</td>
<td>Cardiovascular Disease Risk Reduction in Menopausal Women</td>
<td>Gina P. Lundberg, MD</td>
</tr>
<tr>
<td>10:20am – 10:40am</td>
<td>Gender Differences in Cardiovascular Imaging</td>
<td>Matthew J. Budoff, MD</td>
</tr>
<tr>
<td>10:40am – 11:00am</td>
<td>Sex Differences in DM &amp; CVD Across Outcome Studies</td>
<td>Neha J. Pagidipati, MD</td>
</tr>
<tr>
<td>11:00am – 11:20am</td>
<td>Panel Discussion &amp; Live Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

## Session 6: Advances in Anti-Thrombotics in Diabetes

**Chairs:** Deepak L. Bhatt, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20am – 11:40am</td>
<td>Insights on Anti-thrombotic Strategies in Diabetes from THEMIS and THEMIS PCI</td>
<td>Philippe Gabriel Steg, MD</td>
</tr>
<tr>
<td>11:40am – 12:00pm</td>
<td>Anti-thrombotic Therapy in Diabetes</td>
<td>Richard C. Becker, MD</td>
</tr>
<tr>
<td>12:00pm – 12:20pm</td>
<td>COMPASS</td>
<td>Deepak L. Bhatt, MD</td>
</tr>
<tr>
<td>12:20pm – 12:40pm</td>
<td>Panel Discussion &amp; Live Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
12:00PM AWARD PRESENTATION “LUMINARY IN CARDIOMETABOLIC MEDICINE”
Presented by: Deepak L. Bhatt, MD - Mikhail N. Kosiborod, MD - Yehuda Handelsman, MD

12:45PM KEY NOTE: SGLT2i and the Birth of 2 PARADIGM SHIFTS in Clinical Care
Eugene Braunwald, MD

1:00PM – 1:15PM LIVE Q&A

SESSION 7 PRACTICE RECOMMENDATIONS IN DIABETES & ASCVD – AN UPDATE
Chairs: Lawrence A. Leiter, MD • Sergio Fazio, MD, PhD

2:15pm – 2:30pm Contemporary Lipid Management Recommendations in the Prevention of CVD
Christie M. Ballantyne, MD

2:30pm – 2:45pm ESC/EASD 2019 CVD in DM Guidelines
Peter J. Grant, MD

2:45pm – 3:00pm ADA-EASD Practice Recommendations 2019 Update
David A. D’Alessio, MD

3:00pm – 3:15pm AACE DM & Lipids Practice Recommendations
Yehuda Handelsman, MD

3:15pm – 3:35pm Panel Discussion & Live Q&A

CME SUPPORTED SYMPOSIUM: THE PREVENTION AND MANAGEMENT OF HEART FAILURE
Chairs: Yehuda Handelsman, MD • Javed Butler, MD

3:35pm – 3:40pm Introduction

3:40pm – 4:00pm Epidemiology and Pathophysiology of HF
Mikhail N. Kosiborod, MD

4:00pm – 4:20pm Preventing HF & HF Adverse Outcomes: A Look at the Evidence
Javed Butler, MD

4:20pm – 4:40pm The Present and Future Management of HFrEF and HFpEF
Biyikem Bozkurt, MD, PhD

4:40pm – 4:55pm Panel Discussion: Practical Management of HF – Case-Based
Panel: Biyikem Bozkurt, MD, PhD • Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD
Christian W. Mende, MD • Muthiah Vaduganathan, MD
Moderator: Javed Butler, MD

4:55pm – 5:15pm Live Q&A

5:15PM – 6:15PM DAY 2 SUMMARY, LIVE Q&A
Panel: Javed Butler, MD • Daniel Einhorn, MD • Yehuda Handelsman, MD • Mikhail Kosiborod, MD • Lawrence Leiter, MD • Norman Lepor, MD • Christian Mende, MD

SESSION 8 MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES
Chairs: George Grunberger, MD • Daniel Einhorn, MD

10:00am – 10:20am Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!)
Silvio E. Inzucchi, MD

10:20am – 10:40am Managing Hyperglycemia in T2DM with Class 4-5 CKD
Vivian A. Fonseca, MD

10:40am – 11:00am The Combination of SGLT2i and GLP1-ra’s Impact on CVD
Ralph A. DeFronzo, MD

11:00am – 11:20am Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control
Richard E. Pratley, MD

11:20am – 11:40am Panel Discussion & Live Q&A

SESSION 9 THE TREATMENT OF DIABETES
Chairs: Ralph A. DeFronzo, MD • Vivian A. Fonseca, MD

DEBATE: EARLY COMBINATION VS SEQUENTIAL THERAPY - IMPACT ON DM & CVD

11:40am – 12:00pm Sequential Therapy
David M. Nathan, MD

12:00pm – 12:20pm Early Combination Therapy
Stefano Del Prato, MD

12:20pm – 12:45pm Panel, Q&A, Audience Voting

12:45PM – 1:30PM PRODUCT THEATER Non-CME Industry Supported Session
The Next Horizon in the Heart Failure Treatment Paradigm for Patients with HFrEF: Results of the Landmark DAPA-HF Clinical Trial
Supported by: AstraZeneca
Johanna Contreras, MD

SESSION 10 HEART IN DIABETES WITH JACC
Chairs: Michael E. Farkouh, MD

1:30pm – 1:35pm Introduction
Michael E. Farkouh, MD

1:35pm – 1:50pm Atrial Fibrillation and Diabetes Mellitus
Allen Wang, MD

1:50pm – 2:05pm Therapeutic Care, Health-Related Quality of Life, & Clinical Outcomes in Comorbid HFrEF and DM: The CHAMP-HF Registry
Muthiah Vaduganathan, MD

2:05pm – 2:20pm Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Daniel Gudbjartsson, PhD

2:20pm – 2:35pm SGLT2 Inhibition and Cardiorenal Protection
Julie A. Lovshin, MD, PhD

2:35pm – 2:50pm Individualizing Revascularization Strategy for Diabetic Patients with Multivessel CAD
David J. Cohen, MD

2:50pm – 3:10pm Panel, Live Q&A

SUNDAY AUGUST 23, 2020
SESSION 11  HEART FAILURE: STATE-OF-THE-ART
Chairs: Matthew J. Budoff, MD • Mansoor Husain, MD

3:10pm – 3:30pm  Impact of Blood Pressure Variability on CHF  Peter Reaven, MD
3:30pm – 3:50pm  HF in DM - Is It Morbidity Not Mortality We Need to Focus on?  Mark Kearney, MD
3:50pm – 4:10pm  Physiologic Monitoring of Heart Failure  Robert J. Chilton, DO
4:10pm – 4:30pm  DAPA-HF and Next Steps with SGLT2 Inhibitors in Heart Failure  John McMurray, MD
4:30pm – 5:00pm  Panel Discussion & Live Q&A

5:00PM – 6:00PM  DAY 3 SUMMARY, LIVE Q&A  |  Panel: Matthew Budoff, MD • Ralph DeFronzo, MD • Vivian Fonseca, MD • Yehuda Handelsman, MD • Mikhail Kosiborod, MD • Muthiah Vaduganathan, MD

SESSION 12  GLP1-RA IN ASCVD & THE KIDNEY
Chairs: Richard E. Pratley, MD • Matthew R. Weir, MD

10:00am – 10:20am  Mechanistic Insights into Cardiovascular Effects of GLP1-ra  Nikoaldas Marx, MD
10:20am – 10:40am  GLP1-ra Impact on the Kidney  Mark E. Cooper, AO, PhD
10:40am – 10:55am  Role of GLP1-ra in Trials in HF Patients  Javed Butler, MD
10:55am – 11:15am  Panel Discussion & Live Q&A

SESSION 13  THE KIDNEY & THE HEART
Chairs: Christian W. Mende, MD • Robert J. Chilton, DO

11:15am – 11:35am  The Role of Sodium Restriction in HF in Type 2 Diabetes  Jeffrey Testani, MD
11:35am – 11:55am  Effect of SGLT2i on BP and CKD Progression: Is it Dependent or Independent of BP?  Matthew R. Weir, MD
11:55am – 12:15pm  How Do SGLT2i Reduce Cardiorenal Outcomes and Atrial Fibrillation  Subbha Verma, MD, PhD
12:15pm – 12:35pm  Impact of Kidney Function on Mortality in the CVOTs  George L. Bakris, MD
12:35pm – 1:00pm  Panel Discussion & Live Q&A

1:00PM – 1:45PM  PRODUCT THEATER  Non-CME Industry Supported Session
Atherosclerotic Cardiovascular Disease (ASCVD) in Diabetes: Identifying High Risk and Reducing the Burden of Elevated LDL-C Levels  Supported by: Novartis  Speaker: Norman Lepor, MD

SESSION 14  TECHNOLOGY & DIGITAL HEALTH
Chair: Christos S. Mantzoros, MD, PhD

1:45pm – 2:05pm  Artificial Intelligence in the Future Management of Cardiovascular Disease and Diabetes  Irving K. Loh, MD
2:05pm – 2:25pm  The Implication of Digital Health for Cardiometabolic Conditions  Michael P. Snyder, PhD
2:25pm – 2:45pm  Is There an App for That? Role of Devices on Diabetes and CVD Management  George Grunberger, MD
2:45pm – 3:00pm  Panel Discussion & Live Q&A

SESSION 15  THE LIVER & THE HEART
Chair: Derek LeRoith, MD, PhD

3:00pm – 3:20pm  NAFLD & the Heart as a Part of the Spectrum of Cardiometabolic Risk  Laurence Sperling, MD
3:20pm – 3:40pm  Emerging Management Options for NAFLD/NASH - Impact on Cardiometabolic Outcomes  Christos S. Mantzoros, MD, PhD
3:40pm – 3:55pm  Panel Discussion & Live Q&A

3:55pm – 4:55pm  ABSTRACT ORAL PRESENTATIONS
2020 Abstract Committee: George Grunberger, MD, Chair • Zachary T. Bloomgarden, MD • Matthew J. Budoff, MD • Vivian A. Fonseca, MD • Norman E. Lepor, MD • Derek LeRoith, MD, PhD • Laurence Sperling, MD
Abstracts will be published in American Heart Journal  Editor-in-Chief: Daniel Mark, MD, MPH

4:55pm – 5:00pm  ORAL ABSTRACT WINNERS AWARD PRESENTATION

5:00PM – 6:00PM  DAY 4 SUMMARY, LIVE Q&A  |  Panel: Ralph DeFronzo, MD • George Grunberger, MD • Yehuda Handelsman, MD • Derek LeRoith, MD, PhD • Christian Mende, MD • Matthew Weir, MD
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yehuda Handelsman, MD</td>
<td>FACP, FNLA, FASPC, MACE Chair &amp; Program Director 4th Heart in Diabetes Medical Director &amp; Principal Investigator The Metabolic Institute of America Tarzana, California</td>
</tr>
<tr>
<td>Mikhail N. Kosiborod MD, FACC, FAHA</td>
<td>Chair &amp; Program Director 4th Heart in Diabetes Professor of Medicine Saint Luke’s Mid America Heart Institute University of Missouri-Kansas City School of Medicine Kansas City, Missouri</td>
</tr>
<tr>
<td>George L. Bakris, MD, MA</td>
<td>Hon. DSc, FASN, FAHA Professor of Medicine Director, AHA Comprehensive Hypertension Center The University of Chicago Medicine Chicago, Illinois</td>
</tr>
<tr>
<td>Christie M. Ballantyne, MD</td>
<td>FACC, FACP Chief, Sections of Cardiology and Cardiovascular Research Professor, Departments of Medicine Genetics and Physiology Director, Center for Cardiometabolic Disease Prevention Baylor College of Medicine Houston, Texas</td>
</tr>
<tr>
<td>Richard C. Becker, MD, FAHA</td>
<td>Professor of Medicine Director, Division of Cardiovascular Health and Diseases Director and Physician-in-Chief University of Cincinnati Heart Lung &amp; Vascular Institute University of Cincinnati College of Medicine Cincinnati, Ohio</td>
</tr>
<tr>
<td>Joshua Beckman, MD, MS</td>
<td>Professor of Medicine Director, Vascular Medicine Section Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC) Vanderbilt University Medical Center Nashville, Tennessee</td>
</tr>
<tr>
<td>Deepak L. Bhatt, MD, MPH</td>
<td>FACC, FAHA, FSCAI, FESC Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart &amp; Vascular Center Professor of Medicine, Harvard Medical School Boston, Massachusetts</td>
</tr>
<tr>
<td>Zachary Bloomgarden, MD</td>
<td>MACE Editor, the Journal of Diabetes <a href="http://www.jdiabetes.com">www.jdiabetes.com</a>, Clinical Professor Icahn School of Medicine at Mount Sinai New York, New York</td>
</tr>
<tr>
<td>Biykem Bozkurt, MD, PhD</td>
<td>FHFSA, FACC, FAHA, FESC FACP President, Heart Failure Society of America The Mary and Gordon Cain Chair “Tex” and Deborah Moncrief, Jr., Chair Professor of Medicine Medical Care Line Executive DeBakey VA Medical Center Director, Winters Center for Heart Failure Research Associate Director Cardiovascular Research Institute Vice-Chair of Medicine Baylor College of Medicine Houston, Texas</td>
</tr>
<tr>
<td>Eugene Braunwald, MD</td>
<td>Distinguished Hersey Professor of Medicine Harvard Medical School Founding Chairman, TIMI Study Group Brigham and Women’s Hospital Boston, Massachusetts</td>
</tr>
<tr>
<td>Matthew J. Budoff, MD</td>
<td>FACC, FAHA Professor of Medicine David Geffen School of Medicine at UCLA Endowed Chair of Preventive Cardiology Program Director, Director of Cardiac CT Lundquist Institute Harbor/UCLA Medical Center Division of Cardiology Los Angeles, California</td>
</tr>
<tr>
<td>Javed Butler, MD, MPH, MBA</td>
<td>Patrick H. Lehan Chair in Cardiovascular Research Professor and Chairman, Department of Medicine University of Mississippi Medical Center Jackson, Mississippi</td>
</tr>
<tr>
<td>Robert J. Chilton, DO, FACP, FACC, FAHA, MACOI, FASCAI</td>
<td>Professor of Medicine Department of Medicine Division of Cardiology The University of Texas Health Science Center San Antonio, Texas</td>
</tr>
<tr>
<td>David J. Cohen, MD, MSc</td>
<td>Professor of Medicine University of Missouri-Kansas City Kansas City, Missouri</td>
</tr>
<tr>
<td>Mark E. Cooper, MB BS, PhD, FRACP</td>
<td>Head, Department of Diabetes Central Clinical School Monash University Senior Endocrinologist Alfred Health Clinic Melbourne, Australia</td>
</tr>
<tr>
<td>David A. D’Alessio, MD</td>
<td>Professor of Medicine Chief, Division of Endocrinology Metabolism and Nutrition Associate Director, Duke Molecular Physiology Institute Durham, North Carolina</td>
</tr>
<tr>
<td>Michael H. Davidson, MD</td>
<td>FACC, FACP, FNLA Professor, Director of the Lipid Clinic The University of Chicago Pritzker School of Medicine Chicago, Illinois</td>
</tr>
<tr>
<td>Ralph A. DeFronzo, MD</td>
<td>Professor of Medicine Chief, Diabetes Division University of Texas Health Science Center at San Antonio (UTHSCSA) Deputy Director, Texas Diabetes Institute San Antonio, Texas</td>
</tr>
</tbody>
</table>
Stefano Del Prato, MD
Professor of Endocrinology and Metabolism
Chief of the Section of Diabetes
University of Pisa, School of Medicine
Pisa, Italy

Daniel Einhorn, MD
FACP, FACE
President, Diabetes and Endocrine Associates Medical Director
Scripps Whittier Diabetes Institute
Past President, American Association of Clinical Endocrinology
Past President, American College of Endocrinology (ACE)
Associate Editor, Journal of Diabetes
La Jolla, California

Stefano Del Prato, MD
Professor of Endocrinology and Metabolism
Chief of the Section of Diabetes
University of Pisa, School of Medicine
Pisa, Italy

Daniel Einhorn, MD
FACP, FACE
President, Diabetes and Endocrine Associates Medical Director
Scripps Whittier Diabetes Institute
Past President, American Association of Clinical Endocrinology
Past President, American College of Endocrinology (ACE)
Associate Editor, Journal of Diabetes
La Jolla, California

Michael E. Farkouh, MD
MSc, FRCP, FACC, FAHA
Peter Munk Chair in Multinational Clinical Trials
Director, Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto
Vice-Chair Research & Professor of Medicine, Department of Medicine
University of Toronto
Toronto, Ontario, Canada

Sergio Fazio, MD, PhD
The William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Vivian A. Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Peter J. Grant, MD
FRCP, FMedSci
Professor of Medicine and Diabetologist
Honorary Consultant Physician, Leeds Teaching Hospitals NHS Trust
Division of Cardiovascular & Diabetes Research
University of Leeds
Leeds, United Kingdom

George Grunberger, MD
FACP, FACE
Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and Molecular Medicine & Genetics
Wayne State University
School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont Visiting Professor, Internal Medicine
First Faculty of Medicine
Charles University, Prague, Czech Republic
Bloomfield Hills, Michigan

Daniel Gudbjartsson, PhD
V.P. of Statistics
deCODE Genetics
Reykjavik, Iceland

Mansoor Husain, BSc
FRCP, MD
Executive Director,
Ted Rogers Centre for Heart Research
Director, Toronto General Hospital Research Institute,
University Health Network
Professor, Department of Medicine,
University of Toronto
Senior Scientist, Toronto General Hospital Research Institute,
University Health Network
Toronto, Canada

Silvio E. Inzucchi, MD
Professor of Medicine
Yale School of Medicine
Clinical Chief, Endocrinology and Medical Director
Yale Diabetes Center
Yale-New Haven Hospital
New Haven, Connecticut

Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
Voluntary Faculty
University of Miami
Miller School of Medicine
The Center for Diabetes & Endocrine Care
Past President, AACE & ACE
Hollywood, Florida

Mark Kearney, MBChB
MRCP, MD
British Heart Foundation Professor of Cardiovascular and Diabetes Research
Leeds Institute of Cardiovascular & Metabolic Medicine
Dean of the School of Medicine
University of Leeds
Leeds, United Kingdom

Lawrence A. Leiter, MDCM
FRCP, FACP, FACE, FAHA
Associate Scientist,
Li Ka Shing Knowledge Institute
Director, Lipid Clinic Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor, Medicine and Nutritional Sciences
University of Toronto
Toronto, Canada

Norman E. Lepor, MD, FACC
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Attending Cardiologist at the Smidt Cedars-Sinai Heart Institute
Director of Clinical Research
Westside Medical Associates of LA
Co-Director of Cardiovascular Imaging
Westside Medical Imaging in Beverly Hills
Los Angeles, California

Derek LeRoith, MD, PhD
FACP
Professor of Medicine
Director of Research
Division of Endocrinology
Diabetes & Bone Disease
Department of Medicine
Icahn School of Medicine at Mt. Sinai
New York, New York
Alice H. Lichtenstein, D.Sc.
Gershoff Professor of Nutrition Science and Policy
Director and Senior Scientist
Cardiovascular Nutrition Laboratory
Tufts University
JM USDA Human Nutrition Research Center on Aging
Executive Editor, Tufts Health and Nutrition Letter
Boston, Massachusetts

Myra A. Lipes, MD
Assistant Professor, Medicine
Harvard Medical School
Assistant Professor, Medicine, Brigham And Women’s Hospital
Investigator, Research Division
Joslin Diabetes Center
Boston, Massachusetts

Irving Kent Loh MD
FACC, FAHA, FCCP, FACP
Chief Medical Officer and Co-Founder, INFERNEDICA
Ventura Heart Institute
Chair, Technology & Innovation, California Chapter,
American College of Cardiology
Member, A/4H, International Telecommunication Union, World Health Organization/UN
Adjunct Lecturer, Department of Medicine, Stanford University
School of Medicine
Thousand Oaks, California

Julie A. Lovshin, MD, PhD
FRCPC
Clinician Scientist
Assistant Professor of Medicine
Division of Endocrinology & Metabolism
University of Toronto
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Gina P. Lundberg, MD
FACC, FAHA
Clinical Director
Emory Women’s Heart Center
Associate Professor of Medicine
Emory University School of Medicine
Division of Cardiology
Atlanta, Georgia

Christos S. Mantzoros, MD
DSc, PhD h.c. mult.
Professor of Medicine
Harvard Medical School and Boston University School of Medicine
Chief of Endocrinology, Diabetes and Metabolism
Boston VA Healthcare System
Director of Human Nutrition, Beth Israel Deaconess Medical Center
Editor-in-Chief, Metabolism Clinical & Experimental
Boston, Massachusetts

Nikolaus Marx, MD
FESC, FAHA
Professor of Medicine / Cardiology
Head of the Department of Internal Medicine
University Hospital RWTH Aachen
Aachen, Germany

John McMurray, BSc (Hons)
MB ChB (Hons), MD, FRCP
FESC, FACC, FAHA, FRSE
FMedSci, OBE
Professor of Medical Cardiology and Deputy Director (Clinical)
Institute of Cardiovascular and Medical Sciences
Honorary Consultant Cardiologist
Queen Elizabeth University Hospital
Glasgow, Scotland

Christian W. Mende, MD
FACP, FACN, FASN, FASH, FAHA
Clinical Professor of Medicine
University of California San Diego
La Jolla, California

Robert J. Mentz, MD
FACC, FAHA, FHFS
Associate Professor of Medicine
Chief, Heart Failure Section
Associate Program Director, Duke Cardiovascular Disease Fellowship
Duke University Medical Center and Duke Clinical Research Institute
Durham, North Carolina

David M. Nathan, MD
Director, Diabetes Center and Clinical Research Center
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Steven E. Nissen, MD, MACC
Chief Academic Officer
Heart and Vascular Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner School of Medicine
at Case Western Reserve University
Cleveland, Ohio

Neha J. Pagidipati, MD, MPH
Assistant Professor of Medicine, Division of Cardiology
Director, Duke Cardiometabolic Prevention Program
Associate Program Director
Cardiology Fellowship
Associate Program Director
DCRI Research Fellowship
Duke Clinical Research Institute
Duke University Medical School
Durham, North Carolina

Richard E. Pratley, MD
Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Orlando, Florida
Kausik Ray, BSc(hons) MBChB, MD, MPhil (Cantab) FRCP (Lon), FRCP (Ed), FACC FESC, FAHA
Professor of Public Health Consultant Cardiologist Deputy Director of The Imperial Clinical Trials Unit Head of Commercial Trials Department of Public Health & Primary Care School of Public Health, Imperial College NIHR ARC National Lead of Cardiovascular Disease EAS President Elect London, United Kingdom

Peter Reaven, MD Professor of Clinical Medicine University of Arizona Director, Diabetes Program Carl T. Hayden VAMC (111E) Research Professor College of Health Solutions Arizona State University Phoenix, Arizona

Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center Carver College of Medicine University of Iowa Iowa City, Iowa

Benjamin M. Scirica, MD, MPH Associate Professor of Medicine, Harvard Medical School Associate Physician Brigham and Women’s Hospital Senior Investigator, TIMI Study Group Boston, Massachusetts

Michael P. Snyder, PhD Professor and Chair of Genetics Director, Center for Genomics and Personalized Medicine Stanford University School of Medicine Stanford, California

Laurence Sperling, MD FACC, FAHA, FACP, FASPC Katz Professor in Preventive Cardiology Director of the Emory Heart Disease Prevention Center Professor of Global Health Hubert Department of Global Health Rollins School of Public Health at Emory University Atlanta, Georgia

Philippe Gabriel Steg, MD FESC, FACC Chief, Department of Cardiology Hôpital Bichat, Assistance Publique-Hôpitaux de Paris Vice President Board of the Assistance Publique-Hôpitaux de Paris Professor of Cardiology, Université Paris - Diderot Director, “Clinical Research in Atherothrombosis” Research Team Coordinator of the iVASC (InnoVations in Atherothrombosis SCience) RHU research consortium Chair of the FACT Chairman of the French National University Council Paris, France

Jeffrey Testani, MD, MTR Associate Professor Director of Heart Failure Research, Section of Cardiovascular Medicine Yale University School of Medicine New Haven, Connecticut

Muthiah Vaduganathan, MD, MPH Cardiologist, Brigham and Women’s Hospital Instructor of Medicine Harvard Medical School Boston, Massachusetts

Subodh Verma, MD, PhD FRCS, FAHA Cardiac Surgeon Professor of Surgery and Pharmacology & Toxicology University of Toronto Canada Research Chair in Cardiovascular Surgery Division of Cardiac Surgery St. Michael’s Hospital Toronto, Ontario, Canada

Allen Wang, MD Duke Center for Atrial Fibrillation Department of Medicine Duke University Medical Center Durham, North Carolina

Matthew R. Weir, MD Professor and Chief Nephrology Division Department of Medicine University of Maryland School of Medicine Baltimore, Maryland

HEART IN DIABETES PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair • Mikhail N. Kosiborod, MD, Chair • Deepak L. Bhatt, MD • Zachary T. Bloomgarden, MD • Biykem Bozkurt, MD, PhD
Matthew J. Budoff, MD • Javed Butler, MD • David Cherney, MD, PhD • Robert J. Chilton, DO • Mark E. Cooper, AO, PhD
Michael H. Davidson, MD • Ralph A. DeFronzo, MD • Daniel Einhorn, MD • Michael E. Farkouh, MD • Sergio Fazio, MD, PhD • Vivian A. Fonseca, MD
Peter J. Grant, MD • George Grunberger, MD • Silvio E. Inzucchi, MD • Paul S. Jellinger, MD • Mark Kearney, MD • Lawrence A. Leiter, MDCM
Norman E. Lepor, MD • Derek LaRoi, MD, PhD • Christos S. Mantzoros, MD, DSc, PhD • Nikolaus Marx, MD • Darren K. McGuire, MD
Christian W. Mende, MD • Richard E. Prattley, MD • Kausik Ray, MD • Peter Reaven, MD • Laurence Sperling, MD • Matthew R. Weir, MD • Renee S. Asp, BS
ATTENDANCE IS FREE!
Free Registration • Free CME
www.heartindianabetes.com/registration
Email: info@tmioa.com
To register by phone: (818) 342-1889

CME ACCREDITATION

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Designation Statement
The PESI Inc. designated this live activity for a maximum of 28 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

MOC Points with ABIM
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 28 MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

International CME
International Physicians are formally eligible for AMA PRA Category 1 Credit™.

Physician Assistants
AAPA accepts Category 1 credit from AoCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CA Nurses
Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEPT-4739, designated the 4th HiD for approximately 28 contact hours.

Pharmacists
For the purpose of recertification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE
The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. This course qualifies for 28 continuing education hours.

Registered Dietitian
For the purpose of recertification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit™.

Satisfactory Completion for credits
All attendees must have completed and turned in a course attendance/evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety.
SAVE THE DATE
5th ANNUAL | HEART iN DIABETES
Live CME Conference | June 18-20, 2021
Grand Hyatt, New York City

ENDORsing ORGANIZATIONS:

ASPC
The American Society for Preventive Cardiology

NIAL
NATIONAL LIPID ASSOCIATION

AMERICAN COLLEGE OF CARIOLOGY

Endocrine Nurses Society

American Society of Endocrine Physician Assistants

American Society for Nutrition
Endurance in Nutrition Research and Practice

FH FOUNDATION

American Diabetes Association®

SVS
Society for Vascular Surgery

IES
INTERNATIONAL ACADEMY OF CARDIOLOGY

WORLD OBESITY

ADCES
Association of Diabetes Care & Education Specialists

AAD\E
American Association of Diabetes Educators
2020 MEDIA PARTNERS

For additional information on
REGISTRATION • SUPPORT • EXHIBITS
(818) 342-1889  |  info@tmioa.com  |  www.heartindiabetes.com